ADRENALIN (epinephrine in sodium chloride) by Pfizer is adrenergic alpha-agonists [moa]. First approved in 2023.
Drug data last refreshed 26m ago · AI intelligence enriched 1w ago
ADRENALIN is an intravenous solution of epinephrine in sodium chloride, an alpha-adrenergic agonist that rapidly stimulates adrenergic receptors to increase blood pressure and cardiac output. It is used in acute care settings for hemodynamic support and management of severe hypotension or shock. The drug works by binding to alpha-1 and beta-adrenergic receptors, triggering sympathomimetic effects.
Recent 2023 approval positions this as a growth-stage product with institutional/hospital formulary penetration; commercial team remains lean given acute-care channel focus and low Part D claims volume.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis
Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection
Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline
Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext
Worked on ADRENALIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moJoining the ADRENALIN team means working on a newly approved, well-protected IV product with established clinical utility in high-acuity hospital settings. Career trajectory focuses on scaling hospital formulary adoption, building relationships with critical-care prescribers, and defending market position against generic entrants over the next 12+ years.